Enfuvirtide injection site reactions

Enfuvirtide injection site reactions have been reviewed and continue to be reported in observational studies... 

Fusion Inhibitors Enfuvirtide (T20) Injectable, in 90 mg (1 mL) No dosage N/A Local injection site reaction Catabolism to... 

Injection site reactions Enfuvirtide Onset first new doses symptoms pain, pruritus, erythema, ecchymosis, warmth, nodules, rarely injection site infection All patients Educate regarding use of sterile technique, solution at room temperature, rotation of injection sites, avoidance of sites with little subcutaneous fat or existing reactions Massaging the area vigorously before and after injection may reduce pain wear loose clothing around injection site areas take warm shower or bath prior to injection Rarely, warm compact or analgesics may be necessary... 

Entry inhibitors Enfuvirtide 84 3.8 90 mg (2) 1.1/0.73 nial hemorrhage Injection-site reactions... 

Administration Give each injection at a site different from the preceding injection site, and only where there is no current injection site reaction from an earlier dose. Do not inject enfuvirtide into moles, scar tissue, bruises, or the navel. 

Local injection site reactions The most common adverse events associated with enfuvirtide use are local injection site reactions. Manifestations may include pain and discomfort, induration, erythema, nodules and cysts, pruritus, and ecchymosis. Pneumonia An increased rate of bacterial pneumonia was observed in subjects treated with enfuvirtide in the phase 3 clinical trials compared with the control arm. Hypersensitivity reactions Hypersensitivity reactions have been associated with enfuvirtide therapy and may recur on rechallenge. Hypersensitivity reactions have included individually and in combination Rash, fever, nausea and vomiting, chills. 

Local injection site reactions including pain/discomfort, induration, erythema, nodules and cysts, pruritus, and ecchymosis were the most frequent adverse events associated with the use of enfuvirtide. 

Enfuvirtide Fusion inhibitor 90 mg subcutaneously bid Store at room temperature as a powder refrigerate once reconstituted Local injection site reactions, hypersensitivity reaction ... 

The most common adverse effects associated with enfuvirtide therapy are local injection site reactions. Hypersensitivity reactions may rarely occur, are of varying severity, and may recur on rechallenge. Eosinophilia has also been noted. In one prospective clinical trial, an increased rate of bacterial pneumonia was noted in patients receiving enfuvirtide. No interactions have been identified that would require the alteration of the dosage of other antiretroviral drugs. 

Enfuvirtide Fusion inhibitor 90 mg bid Reconstitute for subcutaneous administration Local injection site reactions Refrigeration required... 

The most prominent adverse effects of enfuvirtide are injection-site reactions. In 98% of patients, one or more local side effects including pain, erythema, and induration at the site of injection are seen 80% of patients develop... 

Skin Local injection site reactions are common with enfuvirtide. In the TORO 2 study, among the 338 patients given enfuvirtide 98% had at least one injection site reaction. The common signs and symptoms of injection site reactions were induration, erythema, nodules, and cysts only 3.3% discontinued treatment as a result [213 ]. There were similar and consistent findings in the TORO 1 study, which was conducted in North and South America [214 ]. Biopsies of the lesion showed an inflammatory response consistent with a localized hypersensitivity reaction [216 ]. In a 47-year-old man amyloidosis occurred at the injection site [217 ]. 

Ball RA, Kinchelow T. Injection site reactions with the HTV-l fusion inhibitor enfuvirtide. J Am Acad Dermatol 2003 49(5) 826-31. 

Adverse Effects. Enfuvirtide must be administered by subcutaneous injection, and local pain and irritation occurs at the injection site in most patients. Other common side effects include peripheral neuropathy and immune complex reactions that can lead to serious problems including respiratory distress syndrome, kidney dysfunction, and possibly Guillain-Barre syndrome. 

---